Image credit: iStock
Myelodysplastic syndromes (MDS) are a group of bone marrow neoplasms caused by blood cells that are poorly produced or working improperly. A clinical trial led by Steven Z. Pavletic, M.D., Senior Clinician in the Immune Deficiency Cellular Therapy Program, is researching a drug for potential MDS therapy. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Christine McGowan at christine.mcgowan@nih.gov
Clinicaltrials.gov identifier: NCT05148234
NCI Protocol ID: NCI000356
Official Title: A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.